Compass Therapeutics Inc. (CMPX) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Compass Therapeutics Inc. (CMPX)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

2.18

0.18 (9.00%)

At close: Jan 15, 2025, 11:47 AM

undefined% (undefined)

Bid	2.17
Market Cap	299.81M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.35
PE Ratio (ttm)	-6.23
Forward PE	n/a
Analyst	Buy

Ask	2.18
Volume	857,107
Avg. Volume (20D)	972,344
Open	2.04
Previous Close	2.00
Day's Range	2.02 - 2.19
52-Week Range	0.77 - 2.68
Beta	undefined

About CMPX

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascular...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Apr 5, 2021

Employees 32

Stock Exchange NASDAQ

Ticker Symbol CMPX

Website https://www.compasstherapeutics.com

Analyst Forecast

According to 4 analyst ratings, the average rating for CMPX stock is "Buy." The 12-month stock price forecast is $8, which is an increase of 267.14% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Why Price Moved

1 week ago · Source

+30.07%

Compass Therapeutics shares are trading higher aft... Unlock content with Pro Subscription

News

1 month ago · zacks.com

Is Compass Therapeutics, Inc. (CMPX) Stock Outpacing Its Medical Peers This Year?

Here is how Compass Therapeutics, Inc. (CMPX) and Bristol Myers Squibb (BMY) have performed compared to their sector so far this year.

1 month ago · seekingalpha.com

Compass Therapeutics: Near-Term Readout, But Beware The High Stakes In Biliary Cancer

Compass Therapeutics' CTX-009 shows promise in biliary tract cancer, with a 37.5% response rate in phase 2 trials and a pivotal phase 2/3 readout expected in Q1 2025. Financially, CMPX is stable with ...

1 month ago · zacks.com

Down -23.46% in 4 Weeks, Here's Why You Should You Buy the Dip in Compass Therapeutics, Inc. (CMPX)

Compass Therapeutics, Inc. (CMPX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street ana...

2 months ago · zacks.com

What Makes Compass Therapeutics, Inc. (CMPX) a New Buy Stock

Compass Therapeutics, Inc. (CMPX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).